NovoCure Ltd (NVCR) Actualités

Novocure to Participate in Upcoming Investor Conferences

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences: Evercore ISI HealthCONx Conference...

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the...

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users Novocure (NASDAQ: NVCR) announced today that the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Novocure meldet Finanzergebnisse des dritten Quartals 2024

Quartalsnettoumsatz von 155 Millionen USD, Steigerung von 22 % gegenüber dem Vorjahr, mit rekordverdächtigen 4.113 aktiven Patienten in Therapie...

Novocure nomme Christoph Brackmann au poste de directeur financier

Novocure (NASDAQ : NVCR) annonce aujourd’hui que Christoph Brackmann a été nommé au poste de directeur financier de la société (CFO). M...

Novocure ernennt Christoph Brackmann zum Finanzvorstand

Novocure (NASDAQ: NVCR) gab heute bekannt, dass Christoph Brackmann zum nächsten Finanzvorstand (CFO) des Unternehmens ernannt wurde. Christoph...

Form 8-K - Current report

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Novocure (NASDAQ: NVCR) announced today that Christoph Brackmann has been appointed as the company’s next Chief Financial Officer (CFO). Mr...